Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13647455 | 0.93 | DPP4 (0.44) | DPP4JAK3BTKKCNH2DRD2 | |
| SCHEMBL3897385 | 0.93 | DPP4 (0.44) | DPP4JAK3BTKKCNH2 | |
| SCHEMBL13647428 | 0.93 | DPP4 (0.44) | DPP4JAK3BTKKCNH2ALDH1A1 | |
| SCHEMBL13647433 | 0.91 | DPP4 (0.43) | DPP4JAK3BTKKCNH2DRD2 | |
| SCHEMBL13647447 | 0.91 | DPP4 (0.45) | DPP4KCNH2DRD2ALDH1A1 | |
| SCHEMBL13647439 | 0.91 | DPP4 (0.46) | DPP4KCNH2DRD2ALDH1A1 | |
| SCHEMBL13647414 | 0.91 | DPP4 (0.44) | DPP4KCNH2DRD2ALDH1A1 | |
| SCHEMBL13647412 | 0.90 | DPP4 (0.45) | DPP4KCNH2DRD2ALDH1A1 | |
| SCHEMBL13647449 | 0.90 | DPP4 (0.45) | DPP4KCNH2DRD2ALDH1A1 | |
| SCHEMBL13647444 | 0.90 | DPP4 (0.46) | DPP4KCNH2DRD2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601728-B2 | Bicyclic pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7601728-B2 | Bicyclic pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-10-13 | — | — | US | disclosed |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1829877-A1 | BICYCLIC PYRROLE DERIVATIVES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-05 | — | — | EP | disclosed |
| EP-1829877-A1 | BICYCLIC PYRROLE DERIVATIVES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318922-A1 | Bicyclic Pyrrole Derivatives | DPP4, DPP7, DPP3 | DPP4 1/4885JAK3 1785/4885BTK 4063/4885 |
| US-20090192129-A1 | BICYCLIC PYRROLE DERIVATIVES | DPP4, DPP7, DPP3 | DPP4 1/4885JAK3 1535/4885BTK 3962/4885 |
| US-20090149483-A1 | BICYCLIC PYRROLE DERIVATIVES | DPP4, DPP7, DPP3 | DPP4 1/4885JAK3 1535/4885BTK 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.